Cargando…

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

OBJECTIVE: We describe a phase II clinical trial of the combination of ribociclib and letrozole for treatment of relapsed oestrogen receptor (ER)-positive ovarian cancer (OC) and endometrial cancer (EC). The primary endpoint was the proportion of patients alive, progression-free survival (PFS), and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colon-Otero, Gerardo, Zanfagnin, Valentina, Hou, Xiaonan, Foster, Nathan R, Asmus, Erik J, Wahner Hendrickson, Andrea, Jatoi, Aminah, Block, Matthew S, Langstraat, Carrie L, Glaser, Gretchen E, Dinh, Tri A, Robertson, Matthew W, Camoriano, John K, Butler, Kristina A, Copland, John A, Weroha, S John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592247/ https://www.ncbi.nlm.nih.gov/pubmed/33109627 http://dx.doi.org/10.1136/esmoopen-2020-000926

Ejemplares similares

Cost-effectiveness analysis of ribociclib plus letrozole versus palbociclib plus letrozole in the United Kingdom
por: Suri, Gaurav, et al.
Publicado: (2019)

Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
por: Block, Matthew S., et al.
Publicado: (2020)

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
por: Darvishi, Ali, et al.
Publicado: (2023)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
por: O’Shaughnessy, Joyce, et al.
Publicado: (2017)

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
por: Sonke, Gabe S., et al.
Publicado: (2017)

Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature
por: Kazemi, Nazanin Yeganeh, et al.
Publicado: (2022)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Advanced ovarian cancer patients identify opportunities for prehabilitation: A qualitative study
por: Polen-De, Clarissa, et al.
Publicado: (2021)

Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A
por: Torres, Diogo, et al.
Publicado: (2019)

Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application
por: Posocco, Bianca, et al.
Publicado: (2020)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft
por: Glaser, Gretchen, et al.
Publicado: (2015)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
por: Hortobagyi, G N, et al.
Publicado: (2019)

Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts()()
por: Butler, Kristina A., et al.
Publicado: (2017)

Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer
por: Silveira, Catarina, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer
por: Fasching, Peter A, et al.
Publicado: (2021)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole
por: Miller, William R, et al.
Publicado: (2010)

Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review
por: Marina, Djordje, et al.
Publicado: (2022)

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts
por: Liu, Yuanhang, et al.
Publicado: (2019)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
por: De Laurentiis, Michelino, et al.
Publicado: (2022)

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
por: Verma, Sunil, et al.
Publicado: (2018)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting
por: Oberg, Ann L., et al.
Publicado: (2021)

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
por: De Laurentiis, Michelino, et al.
Publicado: (2021)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
por: Turković, Lu, et al.
Publicado: (2022)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
por: Salvador Bofill, Javier, et al.
Publicado: (2022)

Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
por: De Laurentiis, Michelino, et al.
Publicado: (2021)

Letrozole in the neoadjuvant setting: the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

Plasma oestrogens and oestrogen receptors in breast cancer patients.
por: Mason, R. C., et al.
Publicado: (1985)

Nonsurgical management of early-stage endometrial cancer due to obesity: a survey of the practice patterns of current Society of Gynecologic Oncology members
por: Kailasam, Aparna, et al.
Publicado: (2023)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

Pemetrexed for Ovarian Cancer: A Systematic Review of the Published Literature and a Consecutive Series of Patients Treated in a Nonclinical Trial Setting
por: Egloff, Heidi, et al.
Publicado: (2014)

Asphyxiation with a Fentanyl Patch
por: Mansfield, Aaron S., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ratg2kr5g6l272ms41as98tkdm